Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New program aims to close racial gap in liver cancer care

NCT ID NCT06728293

Disease control Sponsor: Indiana University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a culturally tailored support program for Black patients with early-stage liver cancer. The program includes education, help with social needs, and easier access to cancer specialists. Forty participants will be randomly assigned to the program or usual care and followed for six months to see if they get curative treatments faster.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Liver Link support program (patient education, social needs screening, and facilitated cancer care access)
What this could lead to
If successful, this program could help reduce racial disparities in liver cancer treatment and improve access to life-saving therapies for Black patients.
What could go wrong
This is a small pilot study with only 40 participants, so results may not apply broadly. The program may not significantly speed up treatment or improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria • Within UCSF criteria: Candidates are eligible or a standardized MELD or PELD exception if, before completing locoregional therapy, they have lesions that meet one of the following criteria: * One Class 5 lesion greater than 5 cm and less than or equal to 8 cm * two or three Class 5 lesions that meeting all of the following * At least one lesion greater than 3cm * Each lesion less than or equal to 5 cm, and * A total diameter of all lesions less than or equal to 8cm * Four or five Class 5 lesions each less than 3 cm, and a total diameter of all lesions less than or equal to 8 cm. * Between 18-75 years old * Have no more than two visits with an HCC-related provider * Able to read, write, and speak English * Any 1 of the following: * Self-report as Black race (can be multiple races as long as 1 is Black) * Self-report as insured by Medicaid (+/- Medicare) * SVI (Social vulnerability index) \>= .75 * Unmarried Exclusion Criteria * Lacks capacity to provide informed consent, including those with stage 2 HE or higher at the time of consent. * Age over 75 * Last transthoracic echocardiogram with EF\<40% (OK if no prior echo) * BMI over 50 * Patients who, in the investigator's judgment, are unlikely to ever be eligible for liver transplantation or resection at the time of enrollment, with reason documented * Prior history of any solid organ transplant * Non-skin cancer malignancies other than hepatocellular carcinoma in past 2 years unless approved by PI (i.e. cervical cancer, early prostate cancer) * Patients who have undergone resection or waitlisted * Patients near completion of transplant evaluation, PI to determine utility of intervention.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC Racial disparities

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Indiana University School of Medicine

    RECRUITING

    Indianapolis, Indiana, 46202, United States

  • Johns Hopkins University

    RECRUITING

    Baltimore, Maryland, 21218, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.